You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of recombinant VSV vaccines for emerging bunyaviruses

    SBC: Advac Therapeutic LLC            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT Emerging viral infections remain a global threat to human health. Bunyaviruses are the largest order of RNA viruses that includes many clinically relevant human pathogens such as Lassa, Rift Valley Fever and various hantaviruses which cause viral hemorrhagic fever (VHF). SFTSV, or Severe fever with thrombocytopenia syndrome virus, is an emerging tick-borne bunyavirus that ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Optimizing brain penetrance of caspase-6 inhibitors to treat neurodegenerative diseases

    SBC: ELGIA THERAPEUTICS, INC.            Topic: R

    PROJECT SUMMARY/ABSTRACT The cysteine protease caspase-6 (Casp6) has been associated with neurodegenerative diseases for over fifteen years. In Alzheimer’s disease (AD), Casp6 is colocalized with amyloid plaques and tau tangles in human brain, and both human and animal model data indicate that activated Casp6 contributes to neuronal inflammation, neurodegeneration, and cleavage of proteins to to ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. TeleLine: Plug-n-Play Inline Respiratory Remote Data Acquisition System

    SBC: OMNIBUS MEDICAL DEVICES, LLC            Topic: NINR

    Project Summary One in five Americans live in a rural community served by rural hospitals yet only 1% of ICU resources are available to these hospitals. When the level of care required by a patient exceeds the capabilities of the admitting hospital, the patient is transferred to a better-equipped tertiary hospital. Approximately 800,000 patients require mechanical ventilation every year in the Uni ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Structurally engineered furan fatty acids for the treatment of dyslipidemia and cardiovascular disease

    SBC: FURANICA, INC.            Topic: NHLBI

    1 Project Summary2 Cardiovascular risks in dyslipidemia patients are commonly controlled by lowering the LDL-C level using statins.3 However, a significant residual cardiovascular risk persists in patients with additional concurrent risk factors such4 as obesity, diabetes, insulin resistance, and elevated triglyceride-rich lipoproteins. Given the multifaceted5 underlying pathology of cardiovascula ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Feasibility of a mobile application for sleep and circadian rhythms in pediatric patients with acute lymphoblastic leukemia and their caregivers

    SBC: ARCASCOPE INC.            Topic: NHLBI

    ABSTRACT Long-term survival rates for children diagnosed with acute lymphoblastic leukemia (ALL) currently exceed 90%. However, prolonged ALL chemotherapy, which lasts two to three years on average, is associated with significant fatigue and sleep disturbances in both children and their caregivers. In fact, patients and caregivers often identify excess fatigue and sleep disturbances as the most di ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Identification of Mixed NOP/mu partial agonists as lead compounds for treatment ofmethamphetamine use disorder

    SBC: PHOENIX PHARMALABS, INC.            Topic: NIDA

    Abstract Currently, clinically used drug abuse medications exist for treatment of addiction to opiates, alcohol, and nicotine, but not psychostimulants, such as methamphetamine (METH). Compounds that co-activate both nociceptin opioid peptide (NOP) and mu receptors have potential for treatment of drug abuse. In particular, buprenorphine, a partial mu agonist/kappa antagonist, which also acts as a ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Using in-vivo Real-time Biosensor to Evaluate Prodrugs Designed to Prolong Therapeutic Effects for Smoking Cessation.

    SBC: SPACERX LLC            Topic: NIDA

    ABSTRACT Developing drugs that target the central nervous system (CNS) is hampered by an inability to perform direct in vivo preclinical measurements. Here, we propose to identify an optimal smoking cessation drug candidate by monitoring how our newly synthesized prodrugs alter real-time brain dopamine responses to nicotine. Varenicline (CHANTIX®) is the leading FDA-approved oral medication for s ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. The DOVE Device to Prevent Opioid Overdose Deaths: An Armband That Senses Overdose and Automatically Injects Naloxone

    SBC: Altrumed LLC            Topic: NIDA

    ABSTRACT / PROJECT SUMMARY Despite the wide availability of the antidote naloxone, fatal opioid overdoses still occur at a rate of ~50-70,000 / year in the US. The problem is that naloxone requires a bystander to find and diagnose the overdose, find someone who has naloxone, and then properly administer it. Unfortunately, if this does not occur within 5 minutes, the patient will suffer from brain ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Optimizing the synthesis of[18F]FTMP for commercial distribution

    SBC: VELLUM BIOSCIENCES LLC            Topic: NIBIB

    Abstract The development of genetic medicines such as gene and cell therapies like Chimeric Antigen Receptor (CAR) T cells has necessitated new technologies that can monitor the biodistribution of these therapies in human patients. Imaging is particularly well suited to provide such quantitative measurements of a genetic medicine over time. Vellum Biosciences is a platform imaging company geared t ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a novel sensor for the real-time measurement of mitral coaptation force

    SBC: MitralPint Inc.            Topic: NHLBI

    Project Summary The proposed project will develop a breakthrough endovascular sensor technology to allow for real-time quantification of the mitral coaptation force (MCF) of the mitral valve during both open and percutaneous mitral valve repair (MVR). Mitral regurgitation (MR) is the most common heart valve disorder in the U.S. population, with over 2 million individuals affected. Current methods ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government